<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To develop gene expression profiles that characterise KRAS-, BRAF- or PIK3CA-activated- <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e>, and to explore whether these profiles might be helpful in predicting the response to the epidermal growth factor receptor (EGFR) pathway inhibitors better than mutation status alone </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Fresh frozen <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> samples from 381 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients were collected and mutations in KRAS, BRAF and PIK3CA were assessed </plain></SENT>
<SENT sid="2" pm="."><plain>Using microarray data, three individual oncogenic and a combined model were developed and validated in an independent set of 80 CRC patients, and in a dataset from metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients treated with cetuximab </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: 175 tumours (45.9%) harboured oncogenic mutations in KRAS (30.2%), BRAF (11.0%) and PIK3CA (11.5%) </plain></SENT>
<SENT sid="4" pm="."><plain>Activating mutation signatures for KRAS (75 genes), for BRAF (58 genes,) and for PIK3CA (49 genes) were developed </plain></SENT>
<SENT sid="5" pm="."><plain>The development of a combined oncogenic pathway signature-classified <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> as 'activated oncogenic', or as '<z:mp ids='MP_0002169'>wildtype</z:mp>-like' with a sensitivity of 90.3% and a specificity of 61.7% </plain></SENT>
<SENT sid="6" pm="."><plain>The identified signature revealed other mechanisms that can activate ERK/MAPK pathway in KRAS, BRAF and PIK3CA <z:mp ids='MP_0002169'>wildtype</z:mp> patients </plain></SENT>
<SENT sid="7" pm="."><plain>The combined signature is associated with response to cetuximab treatment in patients with metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (HR 2.51, p&lt;0.0009) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: A combined oncogenic pathway signature allows the identification of patients with an active EGFR-signalling pathway that could benefit from downstream pathway inhibition </plain></SENT>
</text></document>